Effect of DVN therapy on the immunologic milieu. scRNA-seq was performed on bone marrow specimens collected from age-matched HDs and baseline/EOS specimens collected from Pts receiving DVN therapy, DV therapy, or decitabine monotherapy (n = 2 per group). Cells were annotated using SingleR based on a Blueprint-Encode reference database. scRNA-seq data were visualized using UMAP. (A) UMAP visualization plots depicting scRNA-seq data obtained from 2 HDs (top, HD-6 and HD-7) and from baseline/EOS samples from Pts receiving DVN therapy (Pts 3 [middle] and 5 [bottom]). (B) The percentages of annotated cell populations in the bone marrow of HDs and Pts with MDS receiving DVN therapy. CLP, common lymphoid progenitor; CMP, common myeloid progenitor; GMP, granulocyte-monocyte progenitor; HSC, hematopoietic stem cell; MEP, megakaryocyte-erythroid progenitor; MPP, multipotent progenitor; Pt, patient; Tcm, central memory T-cell; Tem, effector memory T-cell; Tregs, -regulatory T-cell; UMAP, uniform manifold approximation and projection.